Calcitriol

A better option than vitamin D in denosumab-treated patients with kidney failure?

Carlo Buonerba, Michele Caraglia, Simona Malgieri, Francesco Perri, Davide Bosso, Piera Federico, Matteo Ferro, Mimma Rizzo, Giovannella Palmieri, Giuseppe Di Lorenzo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.

Original languageEnglish
Pages (from-to)149-151
Number of pages3
JournalExpert Opinion on Biological Therapy
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

zoledronic acid
Calcitriol
Vitamin D
Renal Insufficiency
Kidney
Toxicity
Hypocalcemia
Denosumab
Tumors
Creatinine
Bone
Neoplasm Metastasis
Calcium
Bone and Bones
Neoplasms

Keywords

  • bone metastasis
  • calcitriol
  • denosumab
  • zoledronic acid

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Buonerba, C., Caraglia, M., Malgieri, S., Perri, F., Bosso, D., Federico, P., ... Di Lorenzo, G. (2013). Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opinion on Biological Therapy, 13(2), 149-151. https://doi.org/10.1517/14712598.2012.756470

Calcitriol : A better option than vitamin D in denosumab-treated patients with kidney failure? / Buonerba, Carlo; Caraglia, Michele; Malgieri, Simona; Perri, Francesco; Bosso, Davide; Federico, Piera; Ferro, Matteo; Rizzo, Mimma; Palmieri, Giovannella; Di Lorenzo, Giuseppe.

In: Expert Opinion on Biological Therapy, Vol. 13, No. 2, 02.2013, p. 149-151.

Research output: Contribution to journalArticle

Buonerba, C, Caraglia, M, Malgieri, S, Perri, F, Bosso, D, Federico, P, Ferro, M, Rizzo, M, Palmieri, G & Di Lorenzo, G 2013, 'Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure?', Expert Opinion on Biological Therapy, vol. 13, no. 2, pp. 149-151. https://doi.org/10.1517/14712598.2012.756470
Buonerba, Carlo ; Caraglia, Michele ; Malgieri, Simona ; Perri, Francesco ; Bosso, Davide ; Federico, Piera ; Ferro, Matteo ; Rizzo, Mimma ; Palmieri, Giovannella ; Di Lorenzo, Giuseppe. / Calcitriol : A better option than vitamin D in denosumab-treated patients with kidney failure?. In: Expert Opinion on Biological Therapy. 2013 ; Vol. 13, No. 2. pp. 149-151.
@article{027e0af3c500477f9c2679bc1fe5bc86,
title = "Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure?",
abstract = "Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.",
keywords = "bone metastasis, calcitriol, denosumab, zoledronic acid",
author = "Carlo Buonerba and Michele Caraglia and Simona Malgieri and Francesco Perri and Davide Bosso and Piera Federico and Matteo Ferro and Mimma Rizzo and Giovannella Palmieri and {Di Lorenzo}, Giuseppe",
year = "2013",
month = "2",
doi = "10.1517/14712598.2012.756470",
language = "English",
volume = "13",
pages = "149--151",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Calcitriol

T2 - A better option than vitamin D in denosumab-treated patients with kidney failure?

AU - Buonerba, Carlo

AU - Caraglia, Michele

AU - Malgieri, Simona

AU - Perri, Francesco

AU - Bosso, Davide

AU - Federico, Piera

AU - Ferro, Matteo

AU - Rizzo, Mimma

AU - Palmieri, Giovannella

AU - Di Lorenzo, Giuseppe

PY - 2013/2

Y1 - 2013/2

N2 - Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.

AB - Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.

KW - bone metastasis

KW - calcitriol

KW - denosumab

KW - zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84872186108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872186108&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.756470

DO - 10.1517/14712598.2012.756470

M3 - Article

VL - 13

SP - 149

EP - 151

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 2

ER -